Reactive Arthritis versus Rheumatoid Arthritis: A Scenario Walkthrough

Introducing the Case: A Patient Presents with Joint Pain

A 34‑year‑old woman visits her primary care clinic complaining of pain and swelling in her right knee and left ankle that began two weeks ago. She reports mild morning stiffness that improves after she starts moving. She denies any recent trauma but recalls a bout of diarrheal illness three weeks prior, which resolved on its own. Her medical history is otherwise unremarkable and she takes no regular medications.

On examination, the knee shows warmth, effusion, and limited flexion; the ankle is tender with mild swelling. No skin rashes or eye redness are noted. The physician asks about recent infections, gastrointestinal or genitourinary symptoms, and family history of autoimmune disease. The patient mentions no urinary symptoms and says her mother has hypothyroidism.

Based on the acute onset after an infectious episode and the asymmetric joint pattern, the clinician suspects a post‑infectious arthropathy and orders basic labs to look for markers of inflammation and possible triggers. This sets the stage for comparing the presentation with that of a chronic autoimmune arthritis such as rheumatoid arthritis.

Onset Timing and Possible Triggers

Timing is a crucial clue. Reactive arthritis typically appears within a few days to four weeks after an infection, most commonly a gastrointestinal infection with organisms like Salmonella, Shigella, Campylobacter, or a genitourinary infection such as Chlamydia trachomatis. In our scenario, the diarrheal illness three weeks prior fits this window.

Rheumatoid arthritis, by contrast, usually develops insidiously over months to years, without a clear precipitating infection. Joint symptoms evolve gradually, and patients may notice prolonged morning stiffness lasting more than an hour. There is no required preceding illness for the disease to start.

Thus, when a patient reports a recent bout of gastroenteritis or urethritis followed by joint pain, the clinician leans toward reactive arthritis. If the joint complaints have been slowly worsening for many months with no identifiable trigger, rheumatoid arthritis becomes a stronger consideration.

Pattern of Joint Involvement and Extra‑Articular Signs

Joint involvement patterns also differ. Reactive arthritis often affects fewer than five joints, typically large joints of the lower limbs (knees, ankles) and may be asymmetric. Enthesitis—inflammation where tendons attach to bone—can cause heel pain (Achilles or plantar fascia) and is a frequent feature.

Rheumatoid arthritis usually presents with symmetric polyarthritis, involving the small joints of the hands and wrists (metacarpophalangeal and proximal interphalangeal joints) early on, and later may spread to larger joints. Morning stiffness in rheumatoid arthritis tends to be prolonged and improves only after extensive activity.

Extra‑articular manifestations help further differentiate the two. Reactive arthritis can be accompanied by conjunctivitis, urethritis, or skin lesions such as keratoderma blennorrhagicum on the soles. Rheumatoid arthritis may present with rheumatoid nodules, subcutaneous lumps over pressure points, and systemic signs like low‑grade fever or fatigue, but eye inflammation is less common.

Laboratory Tests and Imaging Findings

Laboratory testing provides supportive, though not definitive, evidence. In reactive arthritis, inflammatory markers such as ESR and CRP are often elevated during the acute phase, but rheumatoid factor (RF) and anti‑cyclic citrullinated peptide (anti‑CCP) antibodies are usually negative. HLA‑B27 testing may be positive in a subset, especially when the arthritis follows a gastrointestinal infection.

Rheumatoid arthritis frequently shows positive RF and/or anti‑CCP antibodies, which are part of the classification criteria. Elevated ESR and CRP are also common, reflecting ongoing systemic inflammation. HLA‑B27 is not associated with rheumatoid arthritis and is generally not tested for this condition.

Imaging can reveal differences as well. Early reactive arthritis may show joint effusion and soft‑tissue swelling on ultrasound or MRI, with minimal bony erosion. In rheumatoid arthritis, imaging often demonstrates joint space narrowing, erosive changes, and synovial hypertrophy, particularly in the metacarpophalangeal joints, even in early disease.

Key Diagnostic Distinctions

Putting the clues together, the clinician uses a systematic approach. First, establish the temporal link to infection; if present, reactive arthritis is favored. Second, assess joint pattern: asymmetric large‑joint oligoarthritis points to reactive arthritis, whereas symmetric small‑joint polyarthritis suggests rheumatoid arthritis. Third, examine for extra‑articular signs such as conjunctivitis or urethritis (reactive) versus rheumatoid nodules (rheumatoid).

Serology helps confirm the suspicion. Negative RF and anti‑CCP with a positive HLA‑B27 (if tested) supports reactive arthritis, while positive RF or anti‑CCP leans toward rheumatoid arthritis. However, seronegative rheumatoid arthritis exists, so clinical judgment remains essential.

In our case scenario, the recent diarrheal illness, asymmetric knee and ankle involvement, absence of RF/anti‑CCP, and a positive HLA‑B27 test (hypothetical) lead to a diagnosis of reactive arthritis. Had the patient presented with six‑month history of painful, swollen wrists and fingers, positive RF, and symmetric joint changes, rheumatoid arthritis would be the more likely diagnosis.

Treatment Approaches and Expected Outcomes

Management diverges after diagnosis. Reactive arthritis is often self‑limited; treatment focuses on symptom relief with NSAIDs, physical therapy to maintain range of motion, and, if a triggering infection is identified, appropriate antibiotics (e.g., doxycycline for Chlamydia‑related cases). Most patients improve within three to six months, although a minority experience recurrent or chronic arthritis.

Rheumatoid arthritis requires disease‑modifying anti‑rheumatic drugs (DMARDs) as first‑line therapy to prevent joint damage. Methotrexate is commonly initiated early, possibly combined with biologics if response is inadequate. Ongoing monitoring of disease activity, joint imaging, and laboratory markers guides treatment adjustments.

Prognosis also differs. While many individuals with reactive arthritis return to baseline function, a small proportion develop chronic arthritis or sacroiliitis. Rheumatoid arthritis, if untreated, can lead to progressive joint erosion, deformity, and systemic complications; early aggressive therapy aims to preserve function and improve long‑term outcomes.